Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Age-Related Eye Disease Study 2 (AREDS2): A Multi-center, Randomized Trial of Lutein, Zeaxanthin and Omega-3 Long-Chain Polyunsaturated Fatty Acids (Docosahexaenoic Acid [DHA] and Eicosapentaenoic Acid [EPA]) in Age-Related Macular Degeneration
Brief Summary: Oral supplementation with the Age-Related Eye Disease Study (AREDS) formulation (antioxidant vitamins C and E, beta carotene, and zinc) has been shown to reduce the risk of progression to advanced age-related macular degeneration (AMD). Observational data suggest that increased dietary intake of lutein + zeaxanthin (carotenoids), omega-3 long-chain polyunsaturated fatty acids (docosahexaenoic acid \[DHA\] + eicosapentaenoic acid \[EPA\]), or both might further reduce this risk. AREDS2 was designed to test whether adding lutein + zeaxanthin, DHA + EPA, or lutein + zeaxanthin and DHA + EPA to the AREDS formulation might further reduce the risk of progression to advanced AMD. A secondary goal was to test the effects of eliminating beta carotene and reducing zinc dose in the AREDS formulation.


Options:
A: Intervention Type: BEHAVIORAL; Name: ascorbic acid, vitamin E, beta carotene, selenium, zinc; Assigned to Arm(s): N/A
B: Arm Label: Lutein/Zeaxanthin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lutein/zeaxanthin | Arm Label: DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: DHA/EPA | Arm Label: Lutein/Zeaxanthin + DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lutein/zeaxanthin and DHA/EPA | Arm Label: Placebo/Control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Lutein/zeaxanthin; Assigned to Arm(s): Lutein/Zeaxanthin | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA/EPA; Assigned to Arm(s): DHA/EPA | Intervention Type: DRUG; Name: Lutein/zeaxanthin and DHA/EPA; Assigned to Arm(s): Lutein/Zeaxanthin + DHA/EPA
C: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
D: Arm Label: Folic acid (400mcg) + Vitamin B12 (100 mcg); Type: EXPERIMENTAL; Interventions: Drug: Folate (400mcg) and Vitamin B12 (100 mcg) | Arm Label: Mediated physical activity promotion; Type: EXPERIMENTAL; Interventions: Behavioral: mediated physical activity promotion | Arm Label: Mental health literacy; Type: EXPERIMENTAL; Interventions: Behavioral: Mental health literacy | Arm Label: Placebo tablet; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Nutrition information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Nutrition information | Arm Label: Pain and arthritis management information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: pain and arthritis management information | Intervention Type: DRUG; Name: Folate (400mcg) and Vitamin B12 (100 mcg); Assigned to Arm(s): Folic acid (400mcg) + Vitamin B12 (100 mcg) | Intervention Type: BEHAVIORAL; Name: mediated physical activity promotion; Assigned to Arm(s): Mediated physical activity promotion | Intervention Type: BEHAVIORAL; Name: Mental health literacy; Assigned to Arm(s): Mental health literacy | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo tablet | Intervention Type: BEHAVIORAL; Name: Nutrition information; Assigned to Arm(s): Nutrition information | Intervention Type: BEHAVIORAL; Name: pain and arthritis management information; Assigned to Arm(s): Pain and arthritis management information

Answer: B